申请人:Lilly Industries Limited
公开号:US04304728A1
公开(公告)日:1981-12-08
Compounds are described of the formula ##STR1## in which R.sup.1 is COOR.sup.5, CONHR.sup.5, cyano, 5-tetrazolyl or R.sup.6, where R.sup.5 is hydrogen or C.sub.1-8 alkyl and R.sup.6 is phenyl or naphthyl, the phenyl or naphthyl group being optionally substituted by one or more group selected from halogen, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, hydroxy, benzyloxy, nitro, trifluoromethyl, carboxyl, C.sub.1-4 alkylsulphinyl, C.sub.1-4 alkylsulphonyl, N(R.sup.5).sub.2, NHCOR.sup.5 and SR.sup.5 ; R.sup.2 is R.sup.6 or --CH.dbd.CH--R.sup.6 when R.sup.1 is COOR.sup.5, CONHR.sup.5, cyano or 5-tetrazolyl, or R.sup.2 is --CH.dbd.CH--R.sup.6 when R.sup.1 is R.sup.6 ; R.sup.3 is hydrogen, C.sub.1-6 alkyl, halogen, hydroxy or --OCH.sub.2 R.sup.6 ; and R.sup.4 is hydrogen, C.sub.1-6 alkyl or halogen; and salts thereof. The compounds have pharmaceutical properties and in particular are useful in the treatment of immediate hypersensitivity conditions such as asthma.
该化合物的结构式为##STR1##其中R.sup.1为COOR.sup.5、CONHR.sup.5、氰基、5-四唑基或R.sup.6,其中R.sup.5为氢或C.sub.1-8烷基,R.sup.6为苯基或萘基,苯基或萘基可以选择性地被一个或多个取代基取代,所述取代基选自卤素、C.sub.1-6烷基、C.sub.1-4烷氧基、羟基、苄氧基、硝基、三氟甲基、羧基、C.sub.1-4烷基磺基、C.sub.1-4烷基磺酰基、N(R.sup.5).sub.2、NHCOR.sup.5和SR.sup.5;R.sup.2为R.sup.6或--CH.dbd.CH--R.sup.6,当R.sup.1为COOR.sup.5、CONHR.sup.5、氰基或5-四唑基时,或者当R.sup.1为R.sup.6时,R.sup.2为--CH.dbd.CH--R.sup.6;R.sup.3为氢、C.sub.1-6烷基、卤素、羟基或--OCH.sub.2 R.sup.6;R.sup.4为氢、C.sub.1-6烷基或卤素;以及它们的盐。这些化合物具有药理特性,特别是在治疗哮喘等即时超敏症状方面具有用途。